Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Genmab

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Teclistamab

            Therapeutic Area: Oncology Product Name: JNJ-64007957

            Highest Development Status: Phase II Product Type: Large molecule

            Recipient: Janssen Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 05, 2020

            Details:

            In heavily pretreated patients, the overall response rate (ORR) with teclistamab was 73 percent (16/22) at the recommended subcutaneous (SC) Phase 2 dose (RP2D).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Enapotamab Vedotin

            Therapeutic Area: Oncology Product Name: HuMax-AXL-ADC

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 24, 2020

            Details:

            Genmab will not advance the development of enapotamab vedotin as the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Epcoritamab

            Therapeutic Area: Oncology Product Name: GEN3013

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 05, 2020

            Details:

            The study will evaluate the efficacy and safety of subcutaneous epcoritamab versus investigators’ choice of chemotherapy regimen (either bendamustine and rituximab or gemcitabine, oxaliplatin, and rituximab) in patients with relapsed or refractory DLBCL.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Daratumumab,Hyaluronidase,Cyclophosphamide

            Therapeutic Area: Genetic Disease Product Name: Darzalex

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Janssen Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 05, 2020

            Details:

            The submission is based on the Phase 3 ANDROMEDA study of daratumumab and hyaluronidase-fihj in combination with VCd as treatment for patients with newly diagnosed AL amyloidosis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Camidanlumab tesirine

            Therapeutic Area: Oncology Product Name: ADCT-301

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: ADC Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 30, 2020

            Details:

            The parties have agreed to eliminate the defined divestment process which was agreed in 2013 and that envisaged, among other things, offering the opportunity for third parties to continue the development and commercialization of Cami.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Daratumumab

            Therapeutic Area: Oncology Product Name: Darzalex

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Janssen Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 21, 2020

            Details:

            Second part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant met the primary endpoint of progression-free survival at a pre-planned interim analysis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GEN1042

            Therapeutic Area: Oncology Product Name: GEN1042

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Recipient: InSysBio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 23, 2020

            Details:

            Genmab together with BioNTech, has begun clinical development of an investigational therapy, GEN1042 (DuoBody®-CD40x4-1BB), for solid tumors. GEN1042 is a novel bispecific agonistic antibody targeting CD40 and 4-1BB for priming and activation of tumor-specific immune response.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tisotumab Vedotin

            Therapeutic Area: Oncology Product Name: HuMax-TF-ADC

            Highest Development Status: Phase II Product Type: Large molecule

            Recipient: Seagen

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 21, 2020

            Details:

            Data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent/metastatic cervical cancer shows that Tisotumab vedotin has meaningful clinical activity in curbing the disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tisotumab Vedotin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            Details:

            Results from the phase 2 innovaTV 204 study evaluating tisotumab vedotin in patients with recurrent or metastatic cervical cancer will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Daratumumab,Pomalidomide,Dexamethasone

            Therapeutic Area: Oncology Product Name: Darzalex

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 31, 2020

            Details:

            Phase 3 APOLLO randomized study evaluating subcutaneous daratumumab in combination with pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in relapsed or refractory multiple myeloma met the primary endpoint of improving progression-free survival.